The Lancet, 0140-6736

Journal

  1. 2019
  2. 2018
  3. Simao, M., Wirtz, V. J., Al-Ansary, L. A., Hill, S., Grove, J., Gray, A. L., ... Hogerzeil, H. (2018). A global accountability mechanism for access to essential medicines. LANCET, 392(10163), 2418-2420. https://doi.org/10.1016/S0140-6736(18)32986-6
  4. Jansen, D., Ehrich, J., Azzopardi-Muscat, N., & McKee, M. (2018). Tackling the challenges of child health care. The Lancet, 392(10158), 1621-1621. https://doi.org/10.1016/S0140-6736(18)32160-3
  5. Annane, D., Fuchs-Buder, T., Zoellner, C., Kaukonen, M., & Scheeren, T. W. L. (2018). EMA recommendation to suspend HES is hazardous. The Lancet, 391(10122), 736-737. https://doi.org/10.1016/S0140-6736(18)30254-X
  6. van Brunschot, S., van Grinsven, J., van Santvoort, H. C., Bakker, O. J., Besselink, M. G., Boermeester, M. A., ... Dutch Pancreatitis Study Grp (2018). Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial. The Lancet, 391(10115), 51-58. https://doi.org/10.1016/S0140-6736(17)32404-2
  7. 2017
  8. Wijting, I., Rokx, C., Boucher, C., van Kampen, J., Pas, S., de Vries-Sluijs, T., ... Rijnders, B. (2017). Dolutegravir as maintenance monotherapy for HIV (DOMONO): A phase 2, randomised non-inferiority trial. The Lancet, 4(12), e547-e554. https://doi.org/10.1016/S2352-3018(17)30152-2
  9. Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J-A., Fogo, A. B., ... ISN Global Kidney Health Summit participants (2017). Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. The Lancet, 390(10105), 1888-1917. https://doi.org/10.1016/S0140-6736(17)30788-2
  10. de Jong, M. J., van der Meulen-de Jong, A. E., Romberg-Camps, M. J., Becx, M. C., Maljaars, J. P., Cilissen, M., ... Pierik, M. J. (2017). Telemedicine for management of inflammatory bowel disease (myIBDcoach): A pragmatic, multicentre, randomised controlled trial. The Lancet, 390(10098), 959-968. https://doi.org/10.1016/S0140-6736(17)31327-2
  11. Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., & Lancet Commission Essential Med (2017). Reply: Essential medicines for universal health coverage. The Lancet, 389(10082), 1881-1882.
  12. van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S. B., van der Valk, M., Rietdijk, S., ... Reesink, H. W. (2017). Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: A phase 1B, double-blind, randomised controlled trial. The Lancet, 389(10070), 709-717. https://doi.org/10.1016/S0140-6736(16)31715-9
  13. Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., ... Reich, M. R. (2017). Essential medicines for universal health coverage. The Lancet, 389(10067), 403-476. https://doi.org/10.1016/S0140-6736(16)31599-9
  14. Stroebe, M., Stroebe, W., Schut, H., & Boerner, K. (2017). Grief is not a disease but bereavement merits medical awareness. The Lancet, 389(10067), 347-349. https://doi.org/10.1016/S0140-6736(17)30189-7
  15. Zhou, B., Bentham, J., Di Cesare, M., Bixby, H., Danaei, G., Cowan, M. J., ... NCD Risk Factor Collaboration (2017). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. The Lancet, 389(10064), 37-55. https://doi.org/10.1016/S0140-6736(16)31919-5
  16. Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., & Lancet Commission on Essential Medicines Policies (2017). Essential medicines for universal health coverage - Authors' reply. The Lancet, 389(10082), 1881-1882. https://doi.org/10.1016/S0140-6736(17)31209-6
  17. 2016
  18. Teerlink, J. R., Felker, G. M., McMurray, J. J. V., Solomon, S. D., Adams, K. F., Cleland, J. G. F., ... COSMIC-HFf Investigators (2016). Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. The Lancet, 388(10062), 2895-2903. https://doi.org/10.1016/S0140-6736(16)32049-9
Previous 1 2 3 4 5 6 7 8 ...11 Next

ID: 683330